Documentation a pain management practice should request
Before adding a Wharton's jelly or exosome product line, pain management and physical medicine practices typically ask a distributor for the lot-specific certificate of analysis, a donor eligibility summary, and confirmation of the sterility testing and quarantine process a lot passed through before release. Exosome products and Wharton's jelly products sit under different parts of the federal regulatory framework, so practices generally request that documentation be organized separately by product family rather than bundled into one generic packet.
Precision Biologics makes this documentation available to verified accounts on request rather than publishing it broadly, since the relevant specifications vary by lot.
Indianapolis
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
209- Pain Medicine
- 87
- Physical Medicine & Rehabilitation
- 122
Account verification and ordering access
Every Precision Biologics account is opened against an NPI number, and pricing is released only once that verification is complete. For a pain management practice, this typically means the prescribing physician or a designated office manager supplies NPI details during onboarding before any order is placed.
This verification step is the same regardless of practice size or location, so an Indianapolis practice follows the identical process as a practice anywhere else Precision Biologics ships.
Cold-chain receiving and lot traceability
Cryopreserved products are stored at -80 degrees Celsius and shipped overnight on dry ice in validated containers; lyophilized exosome and Wharton's jelly formats are shelf-stable and handled per the product insert that accompanies each lot. A receiving practice should confirm the shipment's cold-chain indicator on arrival and log the unique lot identifier against the patient record where the product is used, since traceability is tracked at the lot level.
Verifying regulatory standing before you order
Precision Biologics does not provide clinical, dosing, or procedural guidance and encourages Indianapolis-area pain management and physical medicine practices to confirm their own standing with the Indiana medical board and to review the regulatory posture of any Wharton's jelly or exosome product with their own counsel. Precision Biologics supports account setup with registration and licensure documentation and with physician-level calls limited to product documentation.
These products are not FDA approved or licensed for any disease or condition. Information here is for licensed healthcare professionals and is not medical or legal advice.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management clinic in Indianapolis open an account with Precision Biologics?+
Yes, provided the account is tied to a valid NPI number for a licensed physician or practice. Pricing and ordering access are released only after that verification is complete.
Does Precision Biologics distinguish between Wharton's jelly and exosome product documentation for Indianapolis practices?+
Yes. Because the two product families sit under different parts of the federal regulatory framework, documentation such as certificates of analysis and donor eligibility summaries is organized separately by product line.
What should an Indianapolis physical medicine practice confirm before adding a biologics line?+
Precision Biologics recommends confirming current standing with the Indiana medical board and reviewing the product's regulatory posture with the practice's own counsel before any purchasing decision.